Related Experiment Video

Updated: Jul 16, 2026

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
07:46

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

[Pseudomonas aeruginosa and cystic fibrosis: non-antibiotic strategy]

P Foucaud1, A de Truchis, E Tassin

  • 1Service de pédiatrie-néonatologie, centre hospitalier de Versailles, hôpital André-Mignot, 177, rue de Versailles, 78150 Le Chesnay, France pfoucaud@ch-versailles.fr

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|March 21, 2007
PubMed

Insights

Chronic Pseudomonas aeruginosa infections significantly impact cystic fibrosis outcomes. Management involves advanced antibiotics, preventive strategies like physiotherapy and hygiene, and emerging treatments such as macrolides to reduce bacterial virulence.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Microbiology

Context:

  • Pseudomonas aeruginosa is a major cause of poor prognosis in cystic fibrosis (CF) patients.
  • Increased life expectancy in CF is partly due to improved antipseudomonal antibiotic therapies.
  • Antipseudomonal strategies extend beyond antibiotics to encompass comprehensive patient care.

Purpose:

  • To review current and emerging strategies for managing Pseudomonas aeruginosa bronchopulmonary infections in cystic fibrosis.
  • To highlight the multifaceted approach required, including antibiotherapy, prevention, and novel treatments.
  • To discuss the role of macrolides in chronic infections.

Summary:

  • Management of chronic Pseudomonas aeruginosa in CF involves tailored antibiotic regimens (e.g., nebulized and oral ciprofloxacin).
  • Preventive measures include nutritional support, daily chest physiotherapy with recombinant human DNase, anti-inflammatory treatments, and stringent hygiene protocols.
  • Long-term macrolide use in chronic infections demonstrates antibiofilm properties by reducing bacterial virulence factors.

Impact:

  • Optimized management strategies can improve outcomes and life expectancy for cystic fibrosis patients.
  • Early and comprehensive interventions are crucial for controlling Pseudomonas aeruginosa infections.
  • Further research into vaccines and novel therapeutic approaches like macrolides holds promise for future treatment paradigms.

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients07:25

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients

Published on: July 16, 2020

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Gene Regulation in Microbial Communities: Quorum Sensing01:28

Gene Regulation in Microbial Communities: Quorum Sensing

Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Production of Antibiotics01:27

Production of Antibiotics

Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...